Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 20, 2024

Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer.

View Full Paper
Ask AI
Bookmark
Share

Authors

CQChang QiPTPanwen TianWLWeimin Li

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Qi et al. (2024) studied this question.

synapsesocial.com/papers/68e786ffb6db6435876f9d73https://doi.org/10.3779/j.issn.1009-3419.2024.102.06
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.20212021 · 1,017 citations
  2. 2Resection of Non–Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune System2011 · 56 citations
  3. 3Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial2023 · 220 citations
  4. 4Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer2020 · 168 citations
  5. 5Postoperative Complications After Transthoracic Esophagectomy for Cancer of the Esophagus and Gastroesophageal Junction Are Correlated With Early Cancer Recurrence2009 · 277 citations